

Fig. E-1
Box-plot diagram of the total linear wear rate plotted against the histological evaluations for the presence of macrophages for the entire cohort.




Fig. E-3
Two-dimensional scatter diagram of the total linear wear rate plotted against the evaluations for the presence of lymphocytes for the pseudo-tumour group.




Fig. E-2
Box-plot diagram of the total linear wear rate plotted against the histological evaluations for the presence of lymphocytes for the entire cohort.




Fig. E-4
Two-dimensional scatter diagram of the total linear wear rate plotted against the Campbell-ALVAL score.




Fig. E-5
Two-dimensional scatter diagram of the total linear wear rate plotted against the Oxford-ALVAL score.

TABLE E-1 Demographic Data on the Pseudotumor and Control Groups			
	Pseudotumor Group (N = 45)	Control Group (N = 11)	P Value
Age at time of primary procedure* (yr)	54.9 ± 9.6 (28.7 to 71.8)	59.4 ± 12.2 (32.6 to 70.9)	0.1
Sex (no. of hips)			0.07
Male	12	6	
Female	33	5	
Duration of implant survival* (yr)	5.0 ± 2.5 (0.8 to 9.8)	3.6 ± 2.3 (1.2 to 7.9)	0.1
Implant type† (no. of hips)			0.4
BHR	27	4	
C+	16	6	
Cornet	1	1	
Recap	1	0	
Femoral head size* (mm)	46 ± 3.5 (36 to 52)	47.5 ± 5 (40 to 54)	0.1
*The values are given as the mean and the standard deviation, with the range in parentheses. †BHR (Birmingham Hip Resurfacing; Smith & Nephew, Leamington Spa, Birmingham, United Kingdom), C+ (Conserve Plus; Wright Medical, Arlington, Tennessee), Cornet (Corin Group, Cirencester, United Kingdom), Recap (Biomed, Swindon, United Kingdom).			